Zinnat 125mg Film-Coated Tablets

  • Name:

    Zinnat 125mg Film-Coated Tablets

  • Company:
    info
  • Active Ingredients:

    Cefuroxime Axetil

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 06/03/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 28/2/2019

Click on this link to Download PDF directly

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Lyclear Dermal Cream Active Ingredients Permethrin
Medicine Name Malarone Film Coated Tablets Active Ingredients Atovaquone, Proguanil Hydrochloride
Medicine Name Menitorix powder and solvent for solution for injection Active Ingredients Hib/Meningococcal group C combined vaccine
Medicine Name MENJUGATE 10 micrograms suspension for injection (PFS) Active Ingredients Meningococcal group C conjugate vaccine
Medicine Name Menveo, powder and solution for solution for injection Active Ingredients Meningococcal Group A, C, W135 and Y conjugate vaccine
Medicine Name Nucala 100 mg powder for solution for injection Active Ingredients Mepolizumab
Medicine Name Phymet DTF 1mg/ml Syrup Active Ingredients Methadone Hydrochloride
Medicine Name Priorix – Powder and solvent for solution for injection in a pre-filled syringe Active Ingredients Measles Vaccine, Mumps Vaccine, Rubella Vaccine
Medicine Name Relvar Ellipta 184 micrograms/22 micrograms inhalation powder, pre-dispensed Active Ingredients Fluticasone furoate, Vilanterol trifenatate
Medicine Name Relvar Ellipta 92 micrograms/22 micrograms inhalation powder, pre-dispensed Active Ingredients Fluticasone furoate, Vilanterol trifenatate
Medicine Name Requip 0.25 mg film-coated tablets Active Ingredients ropinirole hydrochloride
Medicine Name Requip 1 mg film-coated tablets Active Ingredients ropinirole hydrochloride
Medicine Name Requip 2 mg film-coated tablets Active Ingredients ropinirole hydrochloride
Medicine Name Requip 5 mg film-coated tablets Active Ingredients ropinirole hydrochloride
Medicine Name Requip-Modutab 2 mg prolonged-release tablets Active Ingredients ropinirole hydrochloride
Medicine Name Requip-Modutab 4 mg prolonged-release tablets Active Ingredients ropinirole hydrochloride
Medicine Name Requip-Modutab 8 mg prolonged-release tablets Active Ingredients ropinirole hydrochloride
Medicine Name Rotarix oral suspension in pre-filled oral applicator Active Ingredients Live attenuated rotavirus vaccine
Medicine Name Seretide Diskus Active Ingredients Fluticasone Propionate, Salmeterol Xinafoate
Medicine Name Seretide Evohaler Active Ingredients Fluticasone Propionate, Salmeterol Xinafoate
Medicine Name Serevent Diskus Active Ingredients Salmeterol Xinafoate
Medicine Name Serevent Evohaler Active Ingredients Salmeterol Xinafoate
Medicine Name Seroxat Liquid Active Ingredients Paroxetine hydrochloride hemihydrate
Medicine Name Seroxat Tablets Active Ingredients Paroxetine hydrochloride hemihydrate
Medicine Name Trelegy Ellipta Active Ingredients Fluticasone furoate, Umeclidinium bromide, Vilanterol trifenatate
76 - 100 of 135 items.Total: 6 pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 6 March 2019 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 28 February 2019 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 5 - how to store or dispose
  • Change to section 6 - what the product looks like and pack contents
  • Change to section 6 - date of revision

Updated on 28 February 2019 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 6.1 - List of excipients
  • Change to section 6.2 - Incompatibilities
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 20 June 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 20 June 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 6 - date of revision
  • Improved presentation of PIL

Updated on 19 January 2016 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 6.5 - Nature and contents of container
  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SPC:

Section 4.2 – updated dosing recommendation wording for clarity, minor typographical amendments

Section 4.8 – addition cross-reference to Section 4.4 (500mg tablet only)

Section 5.1 – updated Staphylococcus spp. resistance category

Section 5.2 – minor typographical amendments, alignment with QRD template

Section 5.3 – minor typographical amendments,

Section 6.5 - minor typographical amendments

Section 7 – IE MAH address change

Updated on 19 January 2016 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 18 January 2016 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details
  • Change to improve clarity and readability

Updated on 16 July 2015 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 7 - change to Ireland MAH address

Updated on 15 July 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 13 March 2015 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8- administrative changes and addition of reporting details.
Section 5.1 update to the Microbiological susceptibility table

Updated on 12 March 2015 PIL

Reasons for updating

  • Change of trade or active ingredient name
  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to further information section
  • Change to date of revision

Updated on 28 January 2014 SmPC

Reasons for updating

  • Change due to harmonisation of SPC

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Change due to harmonisation or user testing of the patient leaflet

Updated on 27 January 2014 PIL

Reasons for updating

  • Change due to harmonisation of PIL
  • Change due to user-testing of patient information

Updated on 8 September 2011 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 21 January 2010 SmPC

Reasons for updating

  • Change to section 1 - Name of medicinal product
  • Change to section 2 - Qualitative and quantitative composition

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company



Summary of ZINNAT SPC CHANGES

 

125mg Tablets

 

1.name of the medicinal product

Zinnat 125mg Film-Coated Tablets 125mg

 

2.qualitative and QUantitative composition

Each tablet contains 125mg cefuroxime as cefuroxime axetil.

 

Excipients: Contains approximately 0.10 mg parahydroxybenzoates per tablet.

 

For a full list of excipients see section 6.1

Updated on 11 January 2010 PIL

Reasons for updating

  • Change of trade or active ingredient name
  • Change to storage instructions

Updated on 14 November 2007 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.4 Special Warnings and Precautions for Use

 

[…]

 

As with other antibiotics, prolonged use of cefuroxime may result in the overgrowth of Candida. Prolonged use may also result in the overgrowth of non-susceptible organisms (e.g. Candida, Enterococci and Clostridium difficile), which may require interruption of treatment.

 

[…]

 

4.8 Undesirable Effects

 

[…]

 

Infections and infestations

Common: Candida overgrowth from prolonged use.

 

[…]

Updated on 29 August 2007 PIL

Reasons for updating

  • New PIL for medicines.ie

Updated on 27 September 2006 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.5 Interaction with Other Medicinal Products and Other Forms of Interaction

Drugs which reduce gastric acidity may result in a lower bioavailability of cefuroxime axetil compared with that of the fasting state and tend to cancel the effect of enhanced absorption after food.

In common with other antibiotics, cefuroxime axetil may affect the gut flora, leading to lower oestrogen reabsorption and reduced efficacy of combined oral contraceptives.

As a false negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase methods are used to determine blood/plasma glucose levels in patients receiving cefuroxime axetil. This antibiotic does not interfere in the alkaline picrate assay for creatinine.

4.8............

Infections and infestations

Candida overgrowth from prolonged use............................

Updated on 28 March 2006 SmPC

Reasons for updating

  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 3 July 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)